Literature DB >> 1599025

Peritoneal serous micropapillomatosis of low malignant potential (serous borderline tumors of the peritoneum). A clinicopathologic study of 17 cases.

C V Biscotti1, W R Hart.   

Abstract

Primary peritoneal serous micropapillomatosis of low malignant potential, or serous borderline tumor of the peritoneum, is a relatively rare lesion that is histologically indistinguishable from peritoneal "implants" associated with ovarian papillary serous tumors of low malignant potential. We analyzed 17 cases to further define the pathologic features and prognosis of this entity. The ages of the patients ranged from 16 to 67 years (mean, 33 years). Eight patients were symptomatic with chronic pelvic or abdominal pain (five patients), adnexal mass (one patient), small-bowel obstruction (one patient), and possible endometriosis (one patient). In nine cases (53%), peritoneal serous micropapillomatosis of low malignant potential was an incidental finding discovered during evaluation or treatment of other conditions. Grossly, the peritoneal lesions were focal or diffuse. They commonly appeared as miliary granules and often were believed to be peritoneal carcinomatosis. Microscopically, peritoneal serous micropapillomatosis of low malignant potential had all of the patterns seen in superficial ("noninvasive") peritoneal implants of ovarian serous borderline tumors. Psammoma bodies were a prominent feature of all cases. Twelve patients also had typical endosalpingiosis. Most patients were treated by hysterectomy and bilateral salpingo-oophorectomy. Surgical treatment in seven patients consisted only of biopsy. Ten patients had residual unresected disease at the time of their initial operation. Several patients received adjuvant chemotherapy. Follow-up was available for 14 of the 17 patients. One patient died of metastatic breast carcinoma at 3.8 years; another patient died 7 weeks after operation, possibly as a complication of therapy. The other 12 patients were alive at last known contact after follow-up intervals of 8 months to 16.2 years (mean, 7.5 years). Two of these 12 patients developed multiple episodes of small-bowel obstruction due to persistent peritoneal serous micropapillomatosis of low malignant potential; neither received adjuvant chemo- or radiotherapy. Both were alive without progressive disease 10.9 and 16.2 years after initial diagnosis, respectively. This excellent prognosis supports a regimen of conservative therapy for these patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1599025     DOI: 10.1097/00000478-199205000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  6 in total

1.  Identification of multiple pathways involved in the malignant transformation of endometriosis (Review).

Authors:  Yumi Higashiura; Hirotaka Kajihara; Hiroshi Shigetomi; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2012-04-23       Impact factor: 2.967

2.  CT appearance of primary peritoneal serous borderline tumour: a rare epithelial tumour of the peritoneum.

Authors:  H S Go; H S Hong; J W Kim; J Y Woo
Journal:  Br J Radiol       Date:  2012-01       Impact factor: 3.039

Review 3.  Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Authors:  Murray Joseph Casey; Chhanda Bewtra
Journal:  Fam Cancer       Date:  2004       Impact factor: 2.375

4.  [Pathologic and anatomic evidence of peritoneal metastases].

Authors:  I Tischoff; A Tannapfel
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

Review 5.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25

6.  Concurrent primary peritoneal low-grade serous carcinoma and endometrial high-grade serous carcinoma.

Authors:  Megan G Lockyer; Michael T Deavers; Neda Zarrin-Khameh
Journal:  Int J Gynecol Pathol       Date:  2015-05       Impact factor: 2.762

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.